Merck wins European approval for first-ever Ebola vaccine
FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Linden, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid (Reuters) - Merck & Co Inc on Monday received approval from the European Commission to market (bit.ly/2NZ0QMB) its Ebola vaccine, less than a month after a European medicines panel backed the first-ever vaccine against the deadly virus. The vaccine, Ervebo, is approved for individuals aged 18 years and older and has already been used under emergency guidelines to try to protect against the spread o......
- SUR LE MEME SUJET
FILE PHOTO: The company logo for Johnson & Johnson is displayed to celebrate the 75th anniversary of the company's listing at the New York Stock Exchange (NYSE) in New York, U.S., September 17, 2019. REUTERS/Brendan McDermid (Reuters) - A panel of the European health regulator on Friday recommended approving Johnson & Johnson’s two-dose experimental vaccine for Ebola in the European Union. J&J submitted its application to the European Medicines Agency (EMA) in November for the vaccine, which targets an Ebola strain that causes the ... ...
FILE PHOTO: The company logo for Johnson & Johnson is displayed to celebrate the 75th anniversary of the company's listing at the New York Stock Exchange (NYSE) in New York, U.S., September 17, 2019. REUTERS/Brendan McDermid (Reuters) - A panel of the European health regulator on Friday recommended approving Johnson & Johnson’s two-dose experimental vaccine for Ebola in the European Union. J&J submitted its application to the European Medicines Agency (EMA) in November for its vaccine, which targets an Ebola strain that causes the ... ...
(Reuters) - The U.S. Food and Drug Administration on Friday approved Evofem Biosciences Inc’s birth control gel, ushering in the first non-hormonal contraceptive for women in over three decades. Evofem’s contraceptive gel works by regulating vaginal pH within the normal range of 3.5 to 4.5, creating a hostile environment for the survival of sperm. Reporting by Dania Nadeem and Saumya Sibi Joseph in Bengaluru; Editing by Shinjini Ganguli Our Standards:The Thomson Reuters Trust Principles. ...
FILE PHOTO: The logo of Swiss drugmaker Novartis is pictured at the French company's headquarters in Rueil-Malmaison near Paris, France, April 22, 2020. REUTERS/Charles Platiau ZURICH (Reuters) - Novartis won European approval for its gene therapy Zolgensma for the hereditary disease spinal muscular atrophy (SMA), the Swiss drugmaker said on Tuesday, adding it is in talks over price with countries in hopes of a quick launch. The European Commission gave conditional approval to the therapy, whose U.S. price is $2.1 million, for patient... ...
FILE PHOTO: The logo of Swiss drugmaker Novartis is pictured at the French company's headquarters in Rueil-Malmaison near Paris, France, April 22, 2020. REUTERS/Charles Platiau ZURICH (Reuters) - Swiss drugmaker Novartis said on Tuesday it was awarded conditional European approval for its gene therapy Zolgensma for treating children with the hereditary disease spinal muscular atrophy (SMA). The European Commission approved the therapy, which is priced at $2.1 million in the United States, for the treatment of patients with spinal mus... ...
FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann/File Photo (Reuters) - Swiss drugmaker Roche Holding AG’s Genentech unit said on Monday the U.S. Food and Drug Administration has approved Tecentriq as a standalone therapy for an advanced form of lung cancer. Tecentriq has won the agency's approval for use in previously untreated adults with certain types of metastatic non-small cell lung cancer, the company said. (reut.rs/2ZcrfxH) Reporting b... ...
(Reuters) - The U.S. Food and Drug Administration on Friday approved Bristol Myers Squibb Co’s therapy for previously untreated patients with a form of lung cancer, a much-needed boost as the company battles the dominance of Merck’s Keytruda. The combination of Bristol's treatments, Opdivo and Yervoy, is approved for treating patients with non-small cell lung cancer, the FDA said here Non-small cell lung cancer (NSCLC) accounts for about 85% of lung cancer cases, making it a lucrative market for drugmakers, but one currently dominat... ...
FILE PHOTO: Customers wearing protective masks, face-shields and gloves to prevent infections following the coronavirus disease (COVID-19) outbreak, toast glasses at the cheerleader-themed restaurant 'Cheers One' in Tokyo, Japan May 11, 2020. REUTERS/Kim Kyung-Hoon TOKYO (Reuters) - Japan plans to approve its first coronavirus antigen testing kits on Wednesday, a health ministry official said, in a move to boost the number of diagnostic tests available to battle the pandemic. Fujirebio, a subsidiary of Japanese diagnostics and labor... ...
(Reuters) - The U.S. Food and Drug Administration (FDA) on Saturday approved emergency use authorization (EUA) to Quidel Corp (QDEL.O) for the first COVID-19 antigen test. The emergency use authorization was issued late Friday to Quidel for the Sofia 2 SARS Antigen FIA, the agency said. The FDA said the authorization is for an antigen test, which is a new type of diagnostic test designed for rapid detection of the virus that causes COVID-19. The FDA on Friday also authorized the first diagnostic test for the new coronavirus that allows ... ...
BRATISLAVA (Reuters) - Slovakia on Friday recorded no new cases of coronavirus for the first time since March 10, government figures showed. The central European country of 5.5 million has had fewer cases and deaths than neighbouring countries. Cases total 1,455 while 26 people have died and 919 have already recovered. The government on Wednesday reopened all shops outside shopping malls, hotels, museums, galleries and outdoor tourist attractions and allowed religious services and weddings with a limited number of guests. Schools remain... ...